We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Elevated Collagen XIII Levels Linked to Breast Cancer Metastasis

By LabMedica International staff writers
Posted on 23 Oct 2018
Print article
Image: A micrograph showing a lymph node invaded by ductal breast carcinoma, with an extension of the tumor beyond the lymph node (Photo courtesy of Wikimedia Commons).
Image: A micrograph showing a lymph node invaded by ductal breast carcinoma, with an extension of the tumor beyond the lymph node (Photo courtesy of Wikimedia Commons).
Elevated levels of the transmembrane protein collagen XIII were found to be associated with breast cancer metastasis, cell invasion, anoikis resistance, and poor prognosis for the patient.

Anoikis is a form of programmed cell death that occurs in anchorage-dependent cells when they detach from the surrounding extracellular matrix (ECM). Usually cells stay close to the tissue to which they belong since the communication between proximal cells as well as between cells and ECM provide essential signals for growth or survival. When cells are detached from the ECM, there is a loss of normal cell–matrix interactions, and they may undergo anoikis. However, metastatic tumor cells may escape from anoikis and invade other organs. Cancer cells develop anoikis resistance by several mechanisms, including changes in integrin and matrix signaling, metabolic deregulation, and stress responses of cancer cells.

Investigators at the University of Kentucky (Lexington, USA) analyzed the association of collagen XIII expression with breast cancer development and metastasis using published gene expression profiles generated from human breast cancer tissues, and the used mouse models to investigate roles of collagen XIII in regulating invasive tumor growth. They also inhibited collagen XIII signaling with beta-1 integrin function-blocking antibody.

Integrins are transmembrane receptors that facilitate cell- ECM adhesion. Upon ligand binding, integrins activate signal transduction pathways that mediate cellular signals such as regulation of the cell cycle, organization of the intracellular cytoskeleton, and movement of new receptors to the cell membrane.

Results published in the October 1, 2018, online edition of the journal Breast Cancer Research revealed that expression of collagen XIII was higher in breast cancer tissue compared with normal mammary gland, and that the increased mRNA level of collagen XIII in cancer tissue was associated with poor prognosis and cancer metastasis. They also demonstrated that collagen XIII expression enhanced cancer stem cell-like behavior and invasive tumor growth through beta-1 integrin. Importantly, silencing collagen XIII in breast cancer cells significantly reduced cancer metastasis.

“Understanding how these cancer cells spread and colonize distant organs is crucial for identifying novel strategies to halt the cancer progression and improve cancer treatment,” said senior author Dr. Ren Xu, associate professor pharmacology and nutritional sciences at the University of Kentucky.

Related Links:
University of Kentucky

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
Nutating Mixer
Enduro MiniMix

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.